{
    "Trade/Device Name(s)": [
        "Status DS\u2122 Nicotine",
        "AccuSign\u00ae Nicotine",
        "Biosign Nicotine"
    ],
    "Submitter Information": "Princeton BioMeditech Corporation",
    "510(k) Number": "K062565",
    "Predicate Device Reference 510(k) Number(s)": [
        "K972481"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "MKU"
    ],
    "Summary Letter Date": "January 16, 2007",
    "Summary Letter Received Date": "January 18, 2007",
    "Submission Date": "August 28, 2006",
    "Regulation Number(s)": [
        "21CFR862.3220"
    ],
    "Regulation Name(s)": [
        "Carbon Monoxide test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Cotinine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunoassay",
        "Immunochromatographic test"
    ],
    "Methodologies": [
        "Qualitative detection"
    ],
    "Submission Type(s)": [
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for Status DS\u2122 Nicotine and AccuSign\u00ae Nicotine immunoassay tests for qualitative detection of cotinine in urine",
    "Indications for Use Summary": "Qualitative immunoassay to detect cotinine, a metabolite of nicotine, in human urine at a cut-off of 500 ng/mL as an aid in screening for exposure to nicotine from tobacco or other products",
    "fda_folder": "Toxicology"
}